Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.
Abdullah Zoheb Azhar, MD. Cardiac Amyloid Fellow, University of Pittsburgh Medical Center (UPMC), Pittsburgh Pennsylvania

Main Body of the Abstract
Background and Hypothesis:
ATTR amyloidosis is associated with low transthyretin (TTR, prealbumin) levels while stabilizer therapy is expected to increase it. We investigated the association between baseline and follow up TTR levels after initiation of tafamidis and mortality in ATTR cardiomyopathy.
Methods:
We retrospectively evaluated ATTR cardiomyopathy patients who had prealbumin levels measured at baseline and 6 months after start of therapy. Patients were divided into two groups based on lower prealbumin at follow up than baseline and stable or higher prealbumin than baseline. The hazard ratio was calculated using outcomes cox regression model.
Results
A total of 90 patients were studied (age 77 ± 9 year, 16% women, 24% ATTRv). Median baseline prealbumin was 22mg/dL and median follow up prealbumin was 26mg/dL; 24 patients (26.6%) had a reduction in prealbumin compared to baseline. There was no significant difference in NT proBNP, serum creatinine and interventricular septal thickness on echocardiogram between the two groups. After adjustments of confounding variables; neither the baseline prealbumin level (HR 0.90, CI 0.83-0.98, p 0.2) nor a change in prealbumin at follow up had an association with mortality (HR 0.79, CI 0.17-3.7, p 0.76 for reduction and HR 1.25 CI 0.27-5.86 p 0.76 for stable or increased prealbumin).
Conclusion:
There is no association between baseline TTR levels or its change after 6 months of tafamidis treatment with mortality in patients with ATTR cardiomyopathy

**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Abdullah Zoheb Azhar, MD. Cardiac Amyloid Fellow, University of Pittsburgh Medical Center (UPMC), Pittsburgh Pennsylvania

**Main Body of the Abstract**
**Background and Hypothesis:**
ATTR amyloidosis is associated with low transthyretin (TTR, prealbumin) levels while stabilizer therapy is expected to increase it. We investigated the association between baseline and follow up TTR levels after initiation of tafamidis and mortality in ATTR cardiomyopathy.
**Methods:**
We retrospectively evaluated ATTR cardiomyopathy patients who had prealbumin levels measured at baseline and 6 months after start of therapy. Patients were divided into two groups based on lower prealbumin at follow up than baseline and stable or higher prealbumin than baseline. The hazard ratio was calculated using outcomes cox regression model.
**Results**
A total of 90 patients were studied (age 77 ± 9 year, 16% women, 24% ATTRv). Median baseline prealbumin was 22mg/dL and median follow up prealbumin was 26mg/dL; 24 patients (26.6%) had a reduction in prealbumin compared to baseline. There was no significant difference in NT proBNP, serum creatinine and interventricular septal thickness on echocardiogram between the two groups. After adjustments of confounding variables; neither the baseline prealbumin level (HR 0.90, CI 0.83-0.98, p 0.2) nor a change in prealbumin at follow up had an association with mortality (HR 0.79, CI 0.17-3.7, p 0.76 for reduction and HR 1.25 CI 0.27-5.86 p 0.76 for stable or increased prealbumin).
**Conclusion:**
There is no association between baseline TTR levels or its change after 6 months of tafamidis treatment with mortality in patients with ATTR cardiomyopathy

Lack of an association between baseline or follow-up transthyretin levels and all-cause mortality in ATTR cardiomyopathy patients on tafamidis PC82 (#569)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.